Atopic Dermatitis - Aclaris ATI-045-AD-201

Atopic Dermatitis – Aclaris ATI-045-AD-201

Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.

This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.

Inclusion Criteria:

Diagnosis of chronic atopic dermatitis that has been present for ≥ 6 months before the screening visit and with no significant AD flares during the past 4 weeks before screening
Have active moderate to severe AD at screening and baseline visits
EASI score ≥ 16 and ≥10% BSA at the screening and baseline visits
History of inadequate response to treatment for AD with topical medications; or determination that topical treatments are otherwise medically inadvisable (e.g., because of important side effects or safety risks)
Other criteria may apply

Complete the form and our team will reach out soon to help determine your eligibility.

View Study on ClinicalTrials.gov

Trial Interest Form

I am a...

First Name(Required)

Last Name(Required)

Location(Required)

Phone(Required)

Email(Required)

Gender

Conditions

Race

Contact Preference

How did you hear about us?

Other (Please specify)

This field is hidden when viewing the form

Trial (Origination Page)

This field is hidden when viewing the form

UTM Source

This field is hidden when viewing the form

UTM Medium

This field is hidden when viewing the form

UTM Campaign

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

Phone(Required)

Zip Code(Required)

What is the best way to contact you?(Required)

Comments(Required)

Please let us know what's on your mind. Have a question for us? Ask away.

This field is hidden when viewing the form

Origination Page

Atopic Dermatitis – Aclaris ATI-045-AD-201